GSK (LON:GSK) Insider Acquires £73,981.46 in Stock

GSK plc (LON:GSK) insider Wendy Becker purchased 3,334 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was acquired at an average cost of GBX 2,219 per share, for a total transaction of £73,981.46.

Wendy Becker also recently made the following trade(s):

• On Friday, December 19th, Wendy Becker bought 441 shares of GSK stock. The stock was bought at an average price of GBX 1,809 per share, with a total value of £7,977.69.

GSK Stock Performance

Shares of GSK traded down GBX 2.84 during trading hours on Friday, reaching GBX 2,223.16. 32,758,625 shares of the company’s stock traded hands, compared to its average volume of 9,753,256. The firm has a market capitalization of £89.70 billion, a price-to-earnings ratio of 16.72, a P/E/G ratio of 1.24 and a beta of 0.31. The business’s fifty day simple moving average is GBX 1,915.02 and its two-hundred day simple moving average is GBX 1,716.42. GSK plc has a twelve month low of GBX 1,242.50 and a twelve month high of GBX 2,282. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73.

GSK (LON:GSK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Analysts predict that GSK plc will post 175.980975 earnings per share for the current year.

Wall Street Analyst Weigh In

GSK has been the topic of several research reports. Berenberg Bank boosted their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a research report on Monday, November 24th. Shore Capital Group reiterated a “buy” rating and issued a GBX 2,300 target price on shares of GSK in a report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft increased their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research note on Thursday, January 15th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a research report on Wednesday, January 7th. Finally, Citigroup increased their price objective on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday, February 9th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of GBX 1,917.86.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.